AGE and CALLY Index in Familial Mediterranean Fever

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorBursa City Hospital

About this trial

Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent inflammatory attacks and persistent low-grade inflammation. Even during attack-free periods, subclinical inflammation may continue and contribute to long-term complications.

Advanced glycation end products (AGEs) are molecules that accumulate under chronic inflammatory and oxidative stress conditions. AGEs can be measured non-invasively using skin autofluorescence (SAF). The C-reactive protein-albumin-lymphocyte (CALLY) index is a composite marker derived from routine laboratory parameters and reflects systemic inflammation and nutritional status.

This observational cross-sectional study aims to evaluate the association between skin autofluorescence-measured AGE levels and the CALLY index in patients with FMF. The study will also compare AGE levels between FMF patients and age- and sex-matched healthy controls.

The study does not involve any intervention, treatment assignment, or randomization. All laboratory parameters will be obtained from routine clinical evaluations, and AGE measurement will be performed using a non-invasive device.

Eligibility criteria

Qualifiers

Age between 18 and 65 years

Diagnosis of Familial Mediterranean Fever according to Tel-Hashomer criteria

At least 6 months of clinical follow-up

Available routine laboratory data (CRP, albumin, lymphocyte count)

Disqualifiers

Diagnosis of diabetes mellitus

Chronic kidney disease stage 3 or higher

Active infection

Malignancy within the past 5 years

Trial design

Treatments tested in this trial

  • Skin Autofluorescence Measurement

Treatment groups

150 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators